An increasing evidence indicates that cellular immunotherapy based on DC vaccination has promise to create long-term protection and prevent metastatic spread of tumor. Fortunately， the DC vaccines have minimal side effects， which makes them very tolerable， but their response rate is very slow. This has raised a question that why DC vaccines are not in treating renal cell carcinoma and melanoma as successful in patients with epithelial ovarian cancer. The future strategy to overcome this problem could be to develop such vaccines that contain entire parts of patient’s tumor ......